shutterstock_545879812travellaggio
Travellaggio / Shutterstock.com
12 August 2020AmericasSarah Morgan

McDermott hires Boston pair from Polsinelli

McDermott Will & Emery has strengthened its IP practice in Boston with the addition of Michael Siekman and Jenny Chen as partners.

Before joining  Polsinelli in April last year, both Siekman and Chen served at  Wolf Greenfield.

With more than 25 years of experience, Siekman focuses his practice on patent prosecution, licensing and post-grant proceedings and litigation, advising clients in the biotechnology and pharmaceutical industries.

Chen counsels both US and international clients on patent-related matters in the biotech and life sciences sector, including prosecution, due diligence and post-grant proceedings. She focuses her practice on matters including cell and gene therapies, antibodies, diagnosis and pharmaceutical formulations.

Bill Gaede, leader of the firm’s global IP practice, said: “The last few years have shown an increasing need for breakthrough innovations in the life sciences market.

“Patent protection is essential for bringing necessary technology to market, and Michael and Jenny truly understand what it takes to be a fearless client advocate during every stage of the IP lifecycle.”

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories like this sent straight to your inbox.


More on this story

article
3 March 2020   April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate.
Americas
6 August 2020   The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.

More on this story

article
3 March 2020   April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate.
Americas
6 August 2020   The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.